Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

XLO Xilio Therapeutics, Inc. Common Stock
$7.70 -4.64% -0.38
Notify me if price changes either direction
Interactive Brokers Logotype

Buy XLO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Xilio Therapeutics, Inc. Common Stock (XLO)

Loading

Key Stats

Market cap. 54.4M
Enterprise value -59180344
Trailing PE 11.846154
Forward PE -13.275862
PEG Ratio -0.13892871706806
Enterprise to EBITDA 1.484
Enterprise to revenue -1.076
Price to book MRQ 0.74338675
Price to sales TTM 0.9887777

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 55.0M
EBITDA -39869000
Diluted EPS TTM 0.65
Total Cash (MRQ) 122.2M
Current ratio (MRQ) 4.72
Operating Cash Flow (TTM) -56897000

XLO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent XLO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.